|1.18||0||0.00||Vol 50.68K||1Y Perf -60.80%|
|Nov 30th, 2023 16:00 DELAYED|
|- -||-0.03 -2.54%|
|Target Price||12.00||Analyst Rating||Hold 3.00|
|Potential %||916.95||Finscreener Ranking||★★★★★ 70.93|
|Insiders Trans % 3/6/12 mo.||-/-/-100||Value Ranking||★★★★★ 73.31|
|Insiders Value % 3/6/12 mo.||-/-/-100||Growth Ranking||★★★★★ 88.74|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-100||Income Ranking||— -|
|Price Range Ratio 52W %||8.70||Earnings Rating||Strong Buy|
|Market Cap||36.09M||Earnings Date||9th Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.29|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||125.61K|
|Avg. Monthly Volume||103.27K|
|Avg. Quarterly Volume||74.72K|
Co-Diagnostics Inc. (NASDAQ: CODX) stock closed at 1.18 per share at the end of the most recent trading day (a 0% change compared to the prior day closing price) with a volume of 50.68K shares and market capitalization of 36.08M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 39 people. Co-Diagnostics Inc. CEO is Dwight H Egan.
The one-year performance of Co-Diagnostics Inc. stock is -60.8%, while year-to-date (YTD) performance is -53.17%. CODX stock has a five-year performance of -43%. Its 52-week range is between 0.975 and 3.33, which gives CODX stock a 52-week price range ratio of 8.70%
Co-Diagnostics Inc. currently has a PE ratio of 5.40, a price-to-book (PB) ratio of 0.58, a price-to-sale (PS) ratio of 2.47, a price to cashflow ratio of 5.30, a PEG ratio of -, a ROA of 12.79%, a ROC of 12.56% and a ROE of 13.80%. The company’s profit margin is 23.36%, its EBITDA margin is 19.80%, and its revenue ttm is $32.82 Million , which makes it $1.06 revenue per share.
Of the last four earnings reports from Co-Diagnostics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.29 for the next earnings report. Co-Diagnostics Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Co-Diagnostics Inc. is Hold (3), with a target price of $12, which is +916.95% compared to the current price. The earnings rating for Co-Diagnostics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Co-Diagnostics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Co-Diagnostics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 18.03, ATR14 : 0.13, CCI20 : -44.11, Chaikin Money Flow : -0.27, MACD : 0.01, Money Flow Index : 50.26, ROC : 3.51, RSI : 48.74, STOCH (14,3) : 24.53, STOCH RSI : 0.27, UO : 36.51, Williams %R : -75.47), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Co-Diagnostics Inc. in the last 12-months were: Brian L. Brown (Buy at a value of $5 697), Brian Lee Brown (Buy at a value of $5 700), Brian Lee Brown (Sold 199 166 shares of value $0 ), Durenard Eugene (Sold 60 833 shares of value $0 ), Dwight Egan (Sold 255 834 shares of value $0 ), James B. Nelson (Sold 30 000 shares of value $0 ), Murphy Ted (Sold 60 833 shares of value $0 ), Serbin Richard (Sold 60 833 shares of value $0 )
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.